Anonymous ID: 6b20a5 Dec. 28, 2022, 8:06 p.m. No.18033814   🗄️.is 🔗kun   >>3828 >>3917 >>4079 >>4149 >>4231

https://mobile.twitter.com/DrJohnB2/status/1607360038703611906

 

Dr John B.

@DrJohnB2

(1/2) Important but hitherto overlooked:

There are “pathogenic antibodies” (PA) that induce an “antibody dependent auto-attack” (ADAA) of cells/tissue. Specific PA against SARS-CoV-2 have been detected. Spike protein PA are especially problematic.

https://researchsquare.com/article/rs-612103/v2

 

Dr John B.

@DrJohnB2

·

Dec 26

Replying to

@DrJohnB2

(2/2)

Interestingly, when the anti-SARS-CoV-2 S1 pathogenic antibodies are mixed with anti-SARS-CoV-2 N antibodies, ADAA is diminished.

Since #Covidvaccination induces anti-SARS-CoV-2 S antibodies, the probability of ADAA will be higher compared to a natural SARS-CoV-2 infection.

Anonymous ID: 6b20a5 Dec. 28, 2022, 8:09 p.m. No.18033828   🗄️.is 🔗kun   >>3917 >>4079 >>4149 >>4231

A drug candidate for treating adverse reactions caused by pathogenic antibodies inducible by COVID-19 virus and vaccines

 

https://www.biorxiv.org/content/10.1101/2021.07.13.452194v2

 

Summary

In a recent study, we reported that certain anti-spike antibodies of COVID-19 and SARS-CoV viruses can have a pathogenic effect through binding to sick lung epithelium cells and misleading immune responses to attack self-cells. We termed this new pathogenic mechanism “Antibody Dependent Auto-Attack” (ADAA). This study explores a drug candidate for prevention and treatment of such ADAA-based diseases. The drug candidate is a formulation comprising N-acetylneuraminic acid methyl ester (NANA-Me), an analog of N-acetylneuraminic acid. NANA-Me acts through a unique mechanism of action (MOA) which is repairment of the missing sialic acid on sick lung epithelium cells. This MOA can block the antibodies’ binding to sick cells, which are vulnerable to pathogenic antibodies. Our in vivo data showed that the formulation significantly reduced the sickness and deaths caused by pathogenic anti-spike antibodies. Therefore, the formulation has the potential to prevent and treat the serious conditions caused by pathogenic antibodies during a COVID-19 infection. In addition, the formulation has potential to prevent and treat the adverse reactions of COVID-19 vaccines because the vaccines can induce similar antibodies, including pathogenic antibodies. The formulation will be helpful in increasing the safety of the vaccines without reducing the vaccine’s efficacy. Compared to existing antiviral drugs, the formulation has a unique MOA of targeting receptors, broad spectrum of indications, excellent safety profile, resistance to mutations, and can be easily produced.

 

>>18033814

Anonymous ID: 6b20a5 Dec. 28, 2022, 8:10 p.m. No.18033832   🗄️.is 🔗kun   >>3917 >>4079 >>4149 >>4231

Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645850/

 

Abstract

Aims of the study

Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID‐19 vaccines could worsen disease upon exposure to challenge or circulating virus.

 

Methods used to conduct the study

Published literature was reviewed to identify preclinical and clinical evidence that COVID‐19 vaccines could worsen disease upon exposure to challenge or circulating virus. Clinical trial protocols for COVID‐19 vaccines were reviewed to determine if risks were properly disclosed.

 

Results of the study

COVID‐19 vaccines designed to elicit neutralising antibodies may sensitise vaccine recipients to more severe disease than if they were not vaccinated. Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralising antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID‐19 disease via antibody‐dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID‐19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.

 

Conclusions drawn from the study and clinical implications

The specific and significant COVID‐19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.

Anonymous ID: 6b20a5 Dec. 28, 2022, 8:12 p.m. No.18033837   🗄️.is 🔗kun   >>3917 >>4079 >>4149 >>4231

Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581376/

 

Abstract

A degraded/dysfunctional immune system appears to be the main determinant of serious/fatal reaction to viral infection (for COVID-19, SARS, and influenza alike). There are four major approaches being employed or considered presently to augment or strengthen the immune system, in order to reduce adverse effects of viral exposure. The three approaches that are focused mainly on augmenting the immune system are based on the concept that pandemics/outbreaks can be controlled/prevented while maintaining the immune-degrading lifestyles followed by much of the global population. The fourth approach is based on identifying and introducing measures aimed at strengthening the immune system intrinsically in order to minimize future pandemics/outbreaks.

 

Specifically, the four measures are: 1) restricting exposure to virus; 2) providing reactive/tactical treatments to reduce viral load; 3) developing vaccines to prevent, or at least attenuate, the infection; 4) strengthening the immune system intrinsically, by a) identifying those factors that contribute to degrading the immune system, then eliminating/reducing them as comprehensively, thoroughly, and rapidly as possible, and b) replacing the eliminated factors with immune-strengthening factors.

 

This paper focuses on vaccine safety. A future COVID-19 vaccine appears to be the treatment of choice at the national/international level. Vaccine development has been accelerated to achieve this goal in the relatively near-term, and questions have arisen whether vaccine safety has been/is being/will be compromised in pursuit of a shortened vaccine development time. There are myriad mechanisms related to vaccine-induced, and natural infection-induced, infections that could adversely impact vaccine effectiveness and safety. This paper summarizes many of those mechanisms.